严重急性呼吸综合征冠状病毒 2 株变异对病毒中和滴度的影响：恢复期血浆的治疗用途。

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.

机构信息

Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom.

MRC Human Immunology Unit, MRC Weatherall Institute, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom.

出版信息

J Infect Dis. 2022 Mar 15;225(6):971-976. doi: 10.1093/infdis/jiab563.

DOI:10.1093/infdis/jiab563

PMID:34751775

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8689936/

Abstract

We compared neutralizing antibody titers of convalescent samples collected before and after the emergence of novel strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), against the wild-type virus and Alpha (B.1.1.7) and Beta (B.1.351) variants. Plasma samples collected in 2020 before emergence of variants showed reduced titers against the Alpha variants, and both sets of samples demonstrated significantly reduced titers against Beta. Comparison of microneutralization titers with those obtained with pseudotype and hemagglutination tests showed a good correlation between their titers and effects of strain variation, supporting the use of these simpler assays for assessing the potency of convalescent plasma against currently circulating and emerging strains of SARS-CoV-2.

摘要

我们比较了在新型严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）出现前后采集的恢复期样本针对野生型病毒以及 Alpha（B.1.1.7）和 Beta（B.1.351）变体的中和抗体滴度。在变体出现之前于 2020 年采集的血浆样本对 Alpha 变体的滴度降低，两组样本对 Beta 的滴度均显著降低。与假型和血凝试验获得的中和滴度进行比较表明，它们的滴度与菌株变异的效果之间具有良好的相关性，支持使用这些更简单的检测方法来评估恢复期血浆对当前流行和出现的 SARS-CoV-2 菌株的效力。